Lucas Bennink

Lucas Bennink

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Biomaterials
Verified
Journal Article
Closed access
LBLucas Bennink
Lucas Bennink
YLYang Li
Yang Li
BKBumjin Kim
Bumjin Kim
ISIk Jae Shin
Ik Jae Shin
BSBoi Hoa San
Boi Hoa San
SYS. Michael Yu
S. Michael Yu

10 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MKMorten Asser Karsdal
Morten Asser Karsdal
TCThomas R. Cox
Thomas R. Cox
Amelia ParkerAmelia Parker
Amelia Parker
NWNicholas Willumsen
Nicholas Willumsen
JSJannie Marie Bülow Sand
Jannie Marie Bülow Sand
SRSylvie Ricard-Blum
Sylvie Ricard-Blum
The extracellular matrix (ECM) is the common denominator of more than 50 chronic diseases. Some of these chronic pathologies lead to enhanced tissue formation and deposition, whereas others are associated with increased tissue degradation, and some exhibit a combination of both, leading to severe tissue alterations. To develop effective therapies for diseases affecting the lung, liver, kidney, skin, intestine, musculoskeletal system, heart, and solid tumors, we need to modulate the ECM’s composition to restore its organization and function. Across diverse organ diseases, there are common denominators and distinguishing factors in this fibroinflammatory axis, which may be used to foster new insights into drug development across disease indications. The 2nd Extracellular Matrix Pharmacology Congress took place in Copenhagen, Denmark, from 17 to 19 June 2024 and was hosted by the International Society of Extracellular Matrix Pharmacology. The event was attended by 450 participants from 35 countries, among whom were prominent scientists who brought together state-of-the-art research on organ diseases and asked important questions to facilitate drug development. We highlight key aspects of the ECM in the liver, kidney, skin, intestine, musculoskeletal system, lungs, and solid tumors to advance our understanding of the ECM and its central targets in drug development. We also highlight key advances in the tools and technology that enable this drug development, thereby supporting the ECM.

13 November 2017 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
BSBoi Hoa San
Boi Hoa San
JHJeongmin Hwang
Jeongmin Hwang
SSSujatha Sampath
Sujatha Sampath
YLYang Li
Yang Li
LBLucas Bennink
Lucas Bennink
SYS. Michael Yu
S. Michael Yu

26 April 2017 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
LBLucas Bennink
Lucas Bennink
DSDaniel J. Smith
Daniel J. Smith
CFCatherine A. Foss
Catherine A. Foss
MPMartin Pomper
Martin Pomper
YLYang Li
Yang Li
SYS. Michael Yu
S. Michael Yu

26 July 2024 in Lab Animal
Verified
Journal Article
Open access
PDF file
MLMarkus Linder
Markus Linder
LBLucas Bennink
Lucas Bennink
RFRichard H. Foxton
Richard H. Foxton
MKMike Kirkness
Mike Kirkness
PWPeter Dwayne Westenskow
Peter Dwayne Westenskow
Subretinal fibrosis is associated with worse visual outcomes in patients with neovascular age-related macular degeneration. As there is a lack of optimal biomarkers and no method that directly detects collagen in the back of the eye, novel tools that monitor fibrosis-related changes in neovascular age-related macular degeneration are needed. Here, using two mouse models (the laser-induced choroidal neovascularization model, and the JR5558 mouse presenting with spontaneous subretinal neovascularization with fibrosis), we imaged active fibrotic lesions using fluorescently labeled collagen hybridizing peptides (CHPs), short peptides that bind to single α-chain collagen structures during collagen remodeling. JR5558 retinal pigment epithelium/choroid flat mounts showed CHP co-staining with fibrosis and epithelial mesenchymal transition-related markers; additionally, CHP histopathology staining correlated with in vivo CHP imaging. After laser-induced choroidal neovascularization, in vivo CHP binding correlated with laser intensity, histopathology CHP and fibronectin staining. Laser-induced choroidal neovascularization showed decreased CHP intensity over time in healing/regressing versus active scars in vivo, whereas increased CHP binding correlated with elevated fibrosis in JR5558 mouse eyes with age. In bispecific angiopoietin 2/vascular endothelial growth factor antibody-treated JR5558 mice, CHPs detected significantly decreased collagen remodeling versus immunoglobulin G control. These results demonstrate the first use of CHPs to directly image remodeling collagen in the eye and as a potential clinical optical biomarker of active subretinal fibrosis associated with ocular neovascularization.